Acadia Pharmaceuticals $ACAD was subject to a fake news attack from CNN earlier this week. This created a nice entry point for NUPLAZID, the Parkinson's psychosis drug supplier. $ACAD, ACADIA Pharmaceuticals Inc. / H1 Tandem Diabetes Care $TNDM bottomed in February.The company has multiple product refresh, defines the standard for T:sliim X2 and G5 integration, is reporting revenue growth and is expecting cash flow break-even by 2H/2019. $TNDM, Tandem Diabetes Care, Inc. / H1 Bonus Pick:Exelixis $EXEL EXEL fell 17% in the last month. The valuation (16x forward earnings) is too attractive to pass up. $EXEL, Exelixis, Inc. / H1